GW Pharmaceuticals

Our vision is to be the global leaders in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet needs.
GW is developing a portfolio of cannabinoid medicines, including Sativex for the treatment of MS spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy.

Type
Public
HQ
Histon, GB
Founded
1998
Size (employees)
496 (est)+28%
GW Pharmaceuticals was founded in 1998 and is headquartered in Histon, GB

GW Pharmaceuticals Office Locations

GW Pharmaceuticals has offices in Histon, London, Carlsbad
Histon, GB
Carlsbad, US
London, GB

GW Pharmaceuticals Metrics

GW Pharmaceuticals Summary

Market capitalization

$3.1 b

Closing share price

$122.5
GW Pharmaceuticals's current market capitalization is $3.1 b.

GW Pharmaceuticals Financials

GW Pharmaceuticals's revenue is £27.3 m in FY, 2013 which is a 9.2% decrease from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

£27.3 m£30 m£28.5 m

Revenue growth, %

10.1%(5%)

Cost of sales

£1.3 m£2.1 m£2.6 m

Gross profit

£26 m£28 m£25.9 m

Gross profit Margin, %

95.3%93.1%90.8%

Operating expense total

£36.5 m£47.6 m£83.2 m

GW Pharmaceuticals Market Value History

GW Pharmaceuticals News

GW Pharmaceuticals Company Life

You may also be interested in